Zo net gelezen op het Yahoo forum:
Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020, the Baron Health Care Fund returned 17.1% (institutional shares). In comparison, the benchmark S&P 500 Index was up 12.15%, while the Russell 3000 Health Care Index was up 10.08%. You should check out Baron’s top 5 stock picks for investors to buy right now, which could be the biggest winners of 2021.
In the Q4 2020 Investor Letter, Baron Health Care Fund highlighted a few stocks and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of them. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is a biopharmaceutical company. In the last three months, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stock gained 25% and on February 16th it had a closing price of $87.40. Here is what Baron Health Care Fund said:
"Arrowhead Pharmaceuticals, Inc. is a biotechnology company developing RNAi therapeutics for a long list of diseases. Shares rose given a multitude of upcoming data readouts, a large financial deal with Takeda, and the prospect of increasing RNAi applications from just the liver to other tissue types (i.e., other diseases). We retain high conviction in Arrowhead and expect it to become a large multinational pharmaceutical company over time."
De bold gemarkeerde delen van het citaat klinken mij als muziek in de oren.